Highly Efficient Synthesis of Cinnamamides from Methyl Cinnamates and Phenylethylamines Catalyzed by Lipozyme^® TL IM under Continuous-Flow Microreactors

Abstract

While a few derivatives of cinnamamides exhibited anti-inflammatory and/ or analgesic activity, in this study, we developed a highly efficient method for the synthesis of cinnamamides from methyl cinnamates and phenylethylamines catalyzed by Lipozyme^® TL IM in continuous-flow microreactors. The reaction parameters and broad substrate range of the new method was studied. Maximum conversion (91.3%) was obtained under the optimal condition of substrate molar ratio of 1:2 (methyl 4-chlorocinnamate: phenylethylamine) at 45 $°\mathrm{C}$ for about 40 min. The remarkable features of this work include short residence time, mild reaction conditions, easy control of the reaction process, and that the catalyst can be recycled or reused, which provide a rapid and economical strategy for the synthesis and design of cinnamamide derivatives for further research on drug activity.

1. Introduction

The discovery of novel anti-inflammatory agents derived from natural active products has attracted a lot of attention from medicinal chemists. Cinnamic acid is a natural organic acid in plants with high safety and a variety of pharmacological activities, such as antioxidant, antimicrobial, anticancer, and anti-inflammatory activities [1,2,3,4,5]. Due to their common occurrence in plants and their low toxicity, cinnamic acid derivatives have been evaluated as pharmacologically active compounds [6]. Among the derivatives, cinnamamides constitute an interesting scaffold within medicinal chemistry; thus, they have been incorporated in several synthetic compounds with therapeutic potentials including neuroprotective, anti-microbial, anti-tyrosinase, and anti-inflammatory properties (Figure 1) [7,8,9,10,11]. Cinnamoyl phenylethylamine derivative is a class of compounds with important biological activity in cinnamamide compounds. Additionally, the phenolic hydroxyl group on the benzene ring enhances the effect of inhibiting the expression of P-selectin, tyrosinase, and cyclooxygenase [11,12]. Cinnamoyl tyramine inhibits the expression of cyclooxygenase II [13] and p-coumarinyl tyramine inhibits yeast α-glucosidase [14] (Figure 1).

Construction of amide bonds is the key to the synthesis of cinnamamide derivatives. Traditional chemical synthesis always used condensation reagents such as 2-ethoxy-1-ethoxycarbonyl-1, 2-dihydroquinoline (EEDQ), dicyclohexylcarbodiimide (DCC) or triazine reagents to synthesize cinnamamide derivatives in N, N-dimethylformamide (DMF), tetrahydrofuran (THF) or pyridine [12,15,16,17,18,19]. However, these methods have problems such as environmental pollution, waste of energy, complexity of recycling and disposal, and may even cause allergic reactions [20,21,22,23,24]. In recent years, a number of new chemical catalysts for amide bond synthesis have been reported, such as iron catalysts, boron catalysts, aluminum catalysts, diacetoxyiodobenzene, and 5-nitro-4,6-dithiocyanatopyrimidine (NDTP), but they also suffered from high temperatures, complicated post-treatment, long reaction times or complicated and toxic catalyst preparation [25,26,27,28,29]. So, it is urgent to develop a highly efficient green technology for the synthesis of cinnamamide derivatives.

Biocatalysis, using enzymes for organic synthesis, has emerged as a powerful tool for the synthesis of active pharmaceutical ingredients [30,31]. Enzymes are employed to enable shorter, more efficient, and more sustainable alternative routes toward small-molecule active pharmaceutical ingredients and are additionally used to perform standard reactions in active pharmaceutical ingredients synthesis more efficiently [32,33,34]. For example, recently, an evolved E. coli cytidine deaminase was used for a simple enzyme-mediated transformation, paving the way for a total greener synthesis of the COVID-19 antiviral Molnupiravir [35]. Lipozyme^® TL IM is a commercial heterogeneous biocatalyst supplied by Novozymes prepared via physical adsorption of the lipase from Thermomyces laguginosus on silica gel particles with a catalyst reactivity of 250 IUN·g⁻¹ [36]. The development and attributes of Lipozyme^® TL IM established the industrial applications for immobilized enzymes, including interesterification of food fats and oils [37,38] and development of biodiesel [39] and lipophilic antioxidants [40,41].

Compared with the traditional chemical synthesis of cinnamamides, there are relatively few studies on enzyme-catalyzed synthesis of cinnamamide derivatives. Novozym^® 435 was used to catalyze the synthesis of coumaroyltyramine derivatives from hydroxycinnamate and phenylethylamines in methyl tert-butyl ether (MTBE) for about 24 h, and 65–93% yields of coumaroyltyramine derivatives were obtained [42]. However, enzymatic chemical reaction also has some shortcomings, such as requiring a long reaction time to obtain the desired yield. In addition, the enzymes that can be used for the synthesis of cinnamamide derivatives need to be further developed.

How to explore enzyme-catalyzed cinnamamide derivatives’ synthesis reactions while improving the efficiency of traditional enzyme catalytic reactions? We think of continuous-flow biocatalysis technology as a solution. In a continuous reactor, the substrates are pumped through the reactor, and the product is collected continuously. This set up improves mass transfer, shortens reaction time, and inhibits the occurrence of side reactions effectively [43,44,45,46,47]. The use of Lipozyme^® TL IM has received significant attention due to its easy recovery from the reaction mixture and recycling, relative inexpensiveness, and the fact that it is suitable for developing continuous-flow processes [48,49]. So, in this work, we developed a highly efficient method for the synthesis and design of cinnamamide derivatives catalyzed by Lipozyme^® TL IM in continuous-flow microreactors (Scheme 1). To the best of our knowledge, this is the first description of the highly efficient synthesis of cinnamamides from methyl cinnamates and phenylethylamines catalyzed by Lipozyme^® TL IM under continuous-flow microreactors. The reaction parameters and broad substrate range of the new method was studied. The reaction conditions were optimized with the choice of mild temperatures and environmentally friendly solvents. At the same time, the reaction time and economic cost were saved. It is hoped to provide a rapid strategy for the synthesis and design of cinnamamide derivatives for further research on drug activity.

2. Results

2.1. Effect of Reaction Media and Catalyst

Reaction media and catalyst are important factors in enzymatic reactions. During our research on cinnamamide derivatives’ synthesis reaction from methyl cinnamates and phenylethylamines catalyzed by enzyme in continuous-flow microreactors, methyl cinnamate (1a) and phenylethylamine (2a) were selected as the model reaction. First, we performed a blank control experiment without the enzyme and found that reactions did not occur. Then, we screened the enzyme and solvent species, chose Lipozyme^® TL IM from Thermomyces lanuginosus and Subtilisin^® from Bacillus licheniformis as a comparison, and tert-amyl alcohol, acetonitrile, DMSO, DMF, tert-butanol, and n-hexane as another control group. Different enzymes have various resistance levels in different reaction systems [50]. The results are shown in

Table 1. The effect of reaction media and catalyst on the enzymatic synthesis of N-phenethylcinnamamide in continuous-flow microreactors ^a.

Entry	Solvent	Catalysts	Log P	Yield b (%)
1	tert-amyl alcohol	Lipozyme® TL IM	1.04	71.2 ± 1.5
2	tert-butanol	Lipozyme® TL IM	0.51	36.2 ± 0.8
3	acetonitrile	Lipozyme® TL IM	−0.33	33.5 ± 1.1
4	n-hexane	Lipozyme® TL IM	3.9	n.d.
5	DMF	Lipozyme® TL IM	−1.0	n.d.
6	DMSO	Lipozyme® TL IM	−1.3	n.d.
7	tert-amyl alcohol	Subtilisin®	1.04	n.d.
8	tert-amyl alcohol	None	1.04	n.d.

^a Reaction conditions: feed 1, 5.0 mmol methyl cinnamate (1a) dissolved in 10 mL tert-amyl alcohol, feed 2, 10.0 mmol phenylethylamine (2a) dissolved in 10 mL tert-amyl alcohol, Lipozyme^® TL IM (catalyst reactivity: 250IUN·g⁻¹) 0.87 g, flow rate 20.8 μL min⁻¹, 30 min residence time at 50 °C. ^b Isolated yield. Yield: 100× (actual received quantity/ideal calculated quantity). The data are presented as average ± SD of triplicate experiments.

; Lipozyme^® TL IM and tert-amyl alcohol can catalyze the reaction with a higher yield (Table 1, entry 1). For the synthesis of N-phenethylcinnamamide catalyzed by Lipozyme^® TL IM, a moderate log P solvent will better promote the reaction. Neither too high nor too low reactions can be carried out. Therefore, Lipozyme^® TL IM and tert-amyl alcohol were selected to synthesize cinnamamide derivatives from methyl cinnamates and phenylethylamines under continuous-flow microreactors.

2.2. Effect of Reaction Temperature

In biocatalysis reactions, reaction temperature affects the catalytic activity of enzymes and the thermodynamic equilibrium of the reaction. Using Lipozyme^® TL IM as catalyst, flow reaction was carried out in tert-amyl alcohol at reaction temperatures of 30 °C to 55 °C for 30 min. With the rise in temperature, there was an increased rate of diffusion since the viscosity of the system was lowered so that mass transfer between the enzyme and the substrate may occur more easily. Moreover, the increase in temperature increased the kinetic energy of the molecules that led to faster and efficient collisions [51,52]. As shown in the Figure 2, when the reaction temperature was 45 °C, the best yield was obtained. However, it is best to avoid temperatures above 45 °C because an excessive increases in temperature can cause irreversible denaturation of the enzyme and a sharp decrease in enzyme activity [53].

2.3. Effect of Substrate Ratio

Methyl cinnamate contains C=C double bonds, which can generate the formation of a side-product resulting from an aza-Michael addition [26,54]. So, a lower concentration of methyl cinnamate inhibited the by-reaction effectively. At the same time, the amidation reaction was a reversible reaction. With the increase in the substrate concentration of the amine, the thermodynamic equilibrium shifted in a direction favorable to the formation of N-phenethylcinnamamide. As seen in Figure 3, a maximum yield of 77.2% was obtained when the molar ratio (methyl cinnamate: phenylethylamine) was 1:2. However, when the molar ratio was increased further, there was a negative impact on the conversion rate. Excessive concentration of the substrate increased the viscosity of the solvent, interfered with mass transfer, changed the polarity of the solvent, and affected the activity of the enzyme, while reducing the economic efficiency [41].

2.4. Effect of Residence Time

Residence time is an important parameter affecting the conversion of reaction. We designed reactions from 20 to 50 min to investigate the effect of residence time on the reaction. As we can see from Figure 4, the optimum yield was reached within 40 min at a flow rate of 15.6 μL/min⁻¹. Therefore, we chose 40 min as the optimal residence time for further research on the synthesis of cinnamamide derivatives under continuous-flow microreactors.

2.5. The Effect of Enzyme Reusability

The reusability of Lipozyme^® TL IM was investigated under optimal conditions. The catalytic activity of the biocatalyst remained practically unaltered in the first two cycles, and after that, a slight decrease in activity could be detected. Additionally, after 8 catalytic cycles of the same enzyme sample, it was found that the catalytic yield of the last catalysis could still reach 46.7% (Figure 5). Such decreased activity after successive reaction cycles could be due to the desorption of immobilized lipase during the continuous flow. In addition, the accumulation of residual starting material and/or products remaining in the biocatalyst microenvironment might also lead to enzyme inactivation [49,53,55].

2.6. Comparing the Synthesis of Cinnamamide Derivatives from Methyl Cinnamates and Phenylethylamines in a Continuous-Flow Microreactor and a Batch Bioreactor

To investigate the effect of enzymatic reactions in different reactors, we optimized the conditions of enzymatic reactions in a continuous-flow microreactor and a batch bioreactor for the synthesis of N-phenethylcinnamamide. (

Table 2. Enzyme-catalyzed synthesis of N-phenethylcinnamamide in a Continuous-Flow Microreactor or a Batch Bioreactor ^a.

Entry	Method	STY (g L−1 h−1)	Yield b (%)
1	A	20.68	84.2 ± 1.2
2	B	1.09	64.3 ± 0.8

^a Reaction conditions: Method A: feed 1, 5.0 mmol methyl cinnamate (1a) dissolved in 10 mL tert-amyl alcohol, feed 2, 10.0 mmol phenylethylamine (2a) dissolved in 10 mL tert-amyl alcohol, Lipozyme^® TL IM (catalyst reactivity: 250IUN·g⁻¹) 0.87 g, flow rate 15.6 μL min⁻¹, 40 min residence time at 45 °C. Method B: batch bioreactor, 5.0 mmol methyl cinnamate (1a), and 10.0 mmol phenylethylamine added to 20 mL tert-amyl alcohol, Lipozyme^® TL IM (catalyst reactivity: 250IUN·g⁻¹) 0.87 g, 200 r min⁻¹, 45 °C, 24 h. ^b Isolated yield. Yield: 100× (actual received quality/ideal calculated quality). The data are presented as average ± SD of triplicate experiments.

) In the batch bioreactor (method B), it took about 24 h to reach the expected yield. However, in the continuous-flow microreactor, better yields were obtained in 40 min (method A). Space–time yield (STY) is a common index to evaluate the production capacity of different reactors [56,57,58,59,60]. Therefore, we calculated STY(g L⁻¹ h⁻¹) to evaluate the productivity in the two reactors and found that the STY in the continuous-flow microreactor was higher. The results suggest that the choice of continuous-flow microreactors is more favorable to improve the efficiency of enzymatic synthesis of cinnamamide derivatives.

$$\mathrm{STY}={\mathrm{m}}_{\mathrm{p}}\times {\mathrm{T}}^{-1}\times {\mathrm{V}}_{\mathrm{R}}^{-1}$$

(1)

where m_p is the mass of the generated product (g), T is the residence time (h), and V_R is the reactor volume (L).

2.7. The Scope and Limitation of the Synthesis of Cinnamamide Derivatives Catalyzed by Lipozyme^® TL IM in Continuous-Flow Microreactors

In the ammonolysis of esters, ammonia can attach to the α-carbon in the carbonyl group of the ester as a nucleophile. The electronic part on the α-carbon is transferred to oxygen, and then the amine cation can provide a proton to the methoxy group to generate methanol leaving the group, thus forming an amide [26]. We further studied the scope and limitations of the enzymatic aminolysis of cinnamate derivatives under continuous-flow microreactors; the reactions of four methyl cinnamate derivatives (methyl cinnamate, methyl trans-p-Coumarate, methyl ferulate, and methyl 4-chlorocinnamate) with four amine compounds (phenylethylamine, tyramine, tryptamine, and 5-methoxytryptamine) were studied under optimal reaction conditions (40 min, 45 °C, tert-amyl alcohol, methyl cinnamate derivative:amine compound = 1:2) in continuous-flow microreactors. As shown in

Table 3. Effect of substrate structure on the synthesis of cinnamamide derivatives catalyzed by Lipozyme^® TL IM in continuous-flow microreactors ^a.

Entry	Methyl Cinnamates	Amine Compounds	Product	Yield b (%)
1				84.2 ± 1.2
2				80.4 ± 0.8
3				60.2 ± 0.7
4				55.2 ± 1.3
5				72.8 ± 0.9
6				67.9 ± 0.6
7				54.4 ± 1.2
8				49.8 ± 0.9
9				62.5 ± 2.4
10				54.5 ± 1.6
11				44.9 ± 0.9
12				44.4 ± 0.8
13				91.3 ± 1.3
14				85.3 ± 1.1
15				67.6 ± 0.7
16				62.6 ± 1.8

^a Reaction conditions: feed 1, 5.0 mmol methyl cinnamate derivative dissolved in 10 mL tert-amyl alcohol, feed 2, 10.0 mmol amine compounds dissolved in 10 mL tert-amyl alcohol, Lipozyme^® TL IM (catalyst reactivity: 250IUN·g⁻¹) 0.87 g, flow rate 15.6 μL min⁻¹, 40 min residence time at 45 °C. ^b Isolated yield. Yield: 100× (actual received quantity/ideal calculated quantity). The data are presented as average ± SD of triplicate experiments.

, we found that the substituents on the benzene ring of the ester would affect the reactivity of the ammonolysis reaction. When there was an electron withdrawing on the benzene ring, it was conducive to the reaction, and when there was an electron-donating group, it reduced the reactivity. Then, we studied the effects of different amine compounds on the reaction and found that the substituents on the benzene ring or indole ring had no significant effect on the reaction, which may be due to the fact that phenylethylamines had a long fat chain and weakened the influence of substituents.

3. Materials and Methods

3.1. Materials

All chemicals in this study were obtained from commercial sources and did not require further purification. Subtilisin^® was purchased from Sigma., and Lipozyme^® TL IM from Thermomyces lanuginosus was purchased from Novo Nordisk (Copenhagen, Denmark). Methyl cinnamate, 5-methoxytryptamine was purchased from Shanghai bide Pharmaceutical Technology Co., Ltd. (Shanghai, China). Methyl trans-p-Coumarate, tyramine was obtained from Aladdin (Shanghai, China). Methyl ferulat, phenylethylamine was obtained from Innochem (Beijing, China). Methyl 4-chlorocinnamate was purchased from Macklin (Shanghai, China). Tryptamine was purchased from Rhawn (Shanghai, China). Harvard Instrument PHD 2000 syringe pump was purchased from Harvard University (Holliston, MA, USA). The flow reactor and Y-mixer were purchased from Beijing Haigui Medical Engineering Design Co., Ltd. (Beijing, China). A 400 MHz NMR spectrometer (Billerica, MA, USA) was also used in this study.

3.2. Experimental Setup and Experiment Conditions

The apparatus configuration used for the synthesis of cinnamamide derivatives in the continuous-flow microreactor is shown in Figure 6 and Figure S1. The experimental setup consisted of five main parts: a syringe pump (Harvard Apparatus Dr. 2000), substrate injectors, a Y-mixer, a flow reactor, and a product collector. Preparation: the flow reactor (2 mm inner diameter) was first filled with 0.87 g Lipozyme^® TL IM with a particle size of 0.3–1.0 mm, reactivity of 250 IUN·g⁻¹, followed by immersing the reactor in a constant temperature water bath at 45 °C. Starting of work: 5.0 mmol methyl cinnamate derivative dissolved in 10 mL tert-amyl alcohol in feed 1 and 10.0 mmol amine dissolved in 10 mL tert-amyl alcohol in feed 2. The two solutions were intersected in the Y-mixer, and the mixed stream was passed through the flow reactor at a flow rate of 15.6 μL min⁻¹ with a residence time of 40 min. The reaction solution was finally collected, evaporated, and dried. Following up: The products were separated by silica gel chromatography (eluent: petroleum ether/ethyl acetate from 10/1 to 2/1). The main products were determined by ¹H NMR and ¹³C NMR.

3.3. Analytical Methods

3.3.1. Thin-Layer Chromatography (TLC)

The developing solvent was petroleum ether/ethyl acetate from 6/1 (v/v) to 1/1 (v/v), and the results are detected under UV light irradiation at 254 nm.

3.3.2. Nuclear Magnetic Resonance (NMR)

The product obtained by column chromatography separation and purification was subjected to ¹H NMR and ¹³C NMR structure confirmation on NMR spectrometer.

N-phenethylcinnamamide (3a). White power. ¹H NMR (400 MHz, DMSO-d₆) δ 8.21 (t, J = 5.6 Hz, 1H), 7.57–7.50 (m, 2H), 7.43–7.14 (m, 9H), 6.59 (d, J = 15.9 Hz, 1H), 3.40–3.27 (m, 2H), 2.76 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.16, 139.62, 138.82, 135.04, 129.66, 129.14, 128.84, 128.56, 127.71, 126.33, 122.31, 40.56, 35.30.

N-(4-hydroxyphenethyl)cinnamamide (3b). White powder. ¹H NMR (500 MHz, DMSO-d₆) δ 9.19 (s, 1H), 8.15 (t, J = 5.7 Hz, 1H), 7.55 (d, J = 7.4 Hz, 2H), 7.45–7.34 (m, 4H), 7.02 (d, J = 8.2 Hz, 2H), 6.72–6.65 (m, 2H), 6.62 (d, J = 15.8 Hz, 1H), 3.34–3.32 (m, 2H), 2.66 (t, J = 7.5 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ: 165.06, 155.77, 138.65, 135.06, 129.60, 129.58, 129.46, 128.99, 127.58, 122.43, 115.27, 40.86, 34.48.

N-(2-(1H-indol-3-yl)ethyl)cinnamamide (3c). Orange yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.81–10.77 (m, 1H), 8.20 (t, J = 5.7 Hz, 1H), 7.55–7.49 (m, 3H), 7.44–7.27 (m, 5H), 7.13 (d, J = 2.3 Hz, 1H), 7.03 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.94 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 6.60 (d, J = 15.8 Hz, 1H), 3.44 (td, J = 7.4, 5.7 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.01, 138.57, 136.36, 135.07, 129.50, 129.05, 127.60, 127.33, 122.79, 122.49, 121.05, 118.39, 118.35, 111.88, 111.49, 39.73, 25.35.

N-(2-(5-methoxy-1H-indol-3-yl)ethyl)cinnamamide (3d). Yellow powder. ¹H NMR (400 MHz, DMSO-d₆) δ 10.66 (s, 1H), 8.23 (q, J = 4.8, 4.2 Hz, 1H), 7.55 (ddd, J = 8.1, 3.4, 1.7 Hz, 2H), 7.48–7.34 (m, 4H), 7.25–7.19 (m, 1H), 7.13 (d, J = 2.5 Hz, 1H), 7.04 (d, J = 2.5 Hz, 1H), 6.74–6.68 (m, 1H), 6.68–6.60 (m, 1H), 3.76–3.72 (m, 3H), 3.46 (td, J = 7.5, 4.2 Hz, 2H), 2.85 (td, J = 7.3, 2.5 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.01, 153.08, 138.56, 135.07, 131.49, 129.50, 129.05, 127.67, 127.59, 123.47, 122.52, 112.13, 111.75, 111.21, 100.20, 55.39, 40.51, 25.35.

(E)-3-(4-hydroxyphenyl)-N-phenethylacrylamide (3e). White powder. ¹H NMR (400 MHz, DMSO-d₆) δ 9.88 (s, 1H), 8.07 (t, J = 5.7 Hz, 1H), 7.34 (dd, J = 24.1, 8.6 Hz, 3H), 7.28–7.17 (m, 5H), 6.80–6.73 (m, 2H), 6.37 (dd, J = 15.8, 1.1 Hz, 1H), 3.40–3.33 (m, 2H), 2.75 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO-d₆) δ 165.64, 159.00, 139.69, 138.92, 129.43, 128.83, 128.55, 126.30, 126.06, 118.76, 115.93, 40.53, 35.38.

(E)-N-(4-hydroxyphenethyl)-3-(4-hydroxyphenyl)acrylamide (3f). White powder. ¹H NMR (400 MHz, DMSO-d₆) δ 9.81 (s, 1H), 9.15 (s, 1H), 7.99 (t, J = 5.7 Hz, 1H), 7.40–7.34 (m, 2H), 7.30 (d, J = 15.7 Hz, 1H), 7.04–6.97 (m, 2H), 6.81–6.74 (m, 2H), 6.71–6.63 (m, 2H), 6.38 (d, J = 15.7 Hz, 1H), 3.32–3.28 (m, 2H), 2.63 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.37, 158.86, 155.70, 138.63, 129.62, 129.55, 129.25, 126.01, 118.83, 115.81, 115.19, 40.75, 34.52.

(E)-N-(2-(1H-indol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide (3g). Orange yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (d, J = 2.6 Hz, 1H), 9.82 (s, 1H), 8.08 (t, J = 5.8 Hz, 1H), 7.54 (dd, J = 7.7, 1.1 Hz, 1H), 7.40–7.28 (m, 4H), 7.15 (d, J = 2.4 Hz, 1H), 7.05 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.96 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.81–6.74 (m, 2H), 6.40 (d, J = 15.8 Hz, 1H), 3.49–3.39 (m, 2H), 2.86 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.47, 158.89, 138.67, 136.36, 129.30, 127.34, 126.06, 122.76, 121.04, 118.93, 118.40, 118.34, 115.85, 111.95, 111.48, 39.67, 25.43.

(E)-3-(4-hydroxyphenyl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)acrylamide (3h). Yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.64–10.60 (m, 1H), 9.81 (s, 1H), 8.06 (t, J = 5.8 Hz, 1H), 7.38–7.30 (m, 2H), 7.28 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.79–6.72 (m, 2H), 6.67 (dd, J = 8.7, 2.4 Hz, 1H), 6.38 (d, J = 15.8 Hz, 1H), 3.71 (s, 3H), 3.39 (dd, J = 14.3, 7.6 Hz, 2H), 2.81 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.47, 158.87, 153.06, 138.64, 131.47, 129.27, 127.67, 126.06, 123.43, 118.96, 115.84, 112.10, 111.80, 111.19, 100.21, 55.39, 48.71, 25.42.

(E)-3-(4-hydroxy-3-methoxyphenyl)-N-phenethylacrylamide (3i). White solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (s, 1H), 8.08 (t, J = 5.7 Hz, 1H), 7.37 (d, J = 15.7 Hz, 1H), 7.33–7.16 (m, 5H), 7.14 (d, J = 2.0 Hz, 1H), 7.01 (dd, J = 8.2, 2.0 Hz, 1H), 6.82 (d, J = 8.1 Hz, 1H), 6.48 (d, J = 15.7 Hz, 1H), 3.81 (s, 3H), 3.47–3.40 (m, 2H), 2.79 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.62, 148.43, 147.98, 139.66, 139.19, 128.78, 128.48, 126.58, 126.23, 121.72, 119.09, 115.82, 110.90, 55.65, 40.49, 35.38.

(E)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)acrylamide (3j). White powder. ¹H NMR (500 MHz, DMSO-d₆) δ 9.37 (s, 1H), 9.13 (s, 1H), 7.94 (t, J = 5.7 Hz, 1H), 7.26 (d, J = 15.7 Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H), 7.00–6.94 (m, 2H), 6.94 (dd, J = 8.2, 2.0 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.68–6.60 (m, 2H), 6.38 (d, J = 15.7 Hz, 1H), 3.76 (s, 3H), 3.28 (s, 2H), 2.60 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ: 165.85, 156.08, 148.72, 148.31, 139.37, 130.02, 129.92, 126.94, 121.99, 119.53, 116.15, 115.60, 111.31, 56.04, 41.12, 34.88.

(E)-N-(2-(1H-indol-3-yl)ethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (3k). Orange solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.85–10.80 (m, 1H), 9.44 (s, 1H), 8.07 (t, J = 5.7 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.44–7.23 (m, 2H), 7.42–6.94 (m, 5H), 6.79 (d, J = 8.1 Hz, 1H), 6.45 (d, J = 15.7 Hz, 1H), 3.80 (s, 3H), 3.52–3.42 (m, 2H), 2.88 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.44, 148.31, 147.91, 138.95, 136.35, 127.33, 126.54, 122.75, 121.60, 121.03, 119.22, 118.38, 118.33, 115.73, 111.92, 111.47, 110.80, 55.60, 40.01, 25.40.

(E)-3-(4-hydroxy-3-methoxyphenyl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)acrylamide (3l). Orange solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.64–10.60 (m, 1H), 9.40 (s, 1H), 8.04 (t, J = 5.7 Hz, 1H), 7.30 (d, J = 15.6 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.08 (t, J = 2.7 Hz, 2H), 7.03–6.92 (m, 2H), 6.75 (d, J = 8.1 Hz, 1H), 6.67 (dd, J = 8.7, 2.4 Hz, 1H), 6.42 (d, J = 15.7 Hz, 1H), 3.76 (s, 3H), 3.71 (s, 3H), 3.41 (q, J = 6.8 Hz, 2H), 2.81 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 165.48, 153.07, 148.31, 147.92, 138.94, 131.49, 127.69, 126.56, 123.44, 121.58, 119.26, 115.75, 112.11, 111.80, 111.19, 110.82, 100.23, 55.62, 55.41, 48.72, 25.42.

(E)-3-(4-chlorophenyl)-N-phenethylacrylamide (3m). White solid, ¹H NMR (400 MHz, DMSO-d₆) δ 8.18 (t, J = 5.7 Hz, 1H), 7.58–7.51 (m, 2H), 7.46–7.41 (m, 2H), 7.36 (d, J = 15.8 Hz, 1H), 7.30–7.13 (m, 5H), 6.58 (d, J = 15.8 Hz, 1H), 3.42–3.34 (m, 2H), 2.74 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 164.82, 139.53, 137.33, 133.99, 133.93, 129.33, 129.08, 128.75, 128.47, 126.24, 123.12, 40.47, 35.21.

(E)-3-(4-chlorophenyl)-N-(4-hydroxyphenethyl)acrylamide (3n). White powder. ¹H NMR (400 MHz, DMSO-d₆) δ 9.18 (s, 1H), 8.16 (t, J = 5.7 Hz, 1H), 7.60–7.53 (m, 2H), 7.50–7.42 (m, 2H), 7.38 (d, J = 15.8 Hz, 1H), 7.04–6.97 (m, 2H), 6.71–6.63 (m, 2H), 6.61 (d, J = 15.8 Hz, 1H), 3.36 (s, 2H), 2.64 (t, J = 7.4 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 164.75, 155.76, 137.25, 134.01, 133.91, 129.60, 129.54, 129.32, 129.07, 123.19, 115.23, 40.83, 34.43.

(E)-N-(2-(1H-indol-3-yl)ethyl)-3-(4-chlorophenyl)acrylamide (3o). Yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.83–10.77 (m, 1H), 8.22 (t, J = 5.8 Hz, 1H), 7.55 (dd, J = 11.4, 8.2 Hz, 3H), 7.49–7.44 (m, 2H), 7.40 (d, J = 15.8 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.15 (d, J = 2.3 Hz, 1H), 7.05 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.96 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 6.62 (d, J = 15.8 Hz, 1H), 3.50–3.41 (m, 2H), 2.87 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 164.77, 137.20, 136.34, 134.04, 133.87, 129.28, 129.05, 127.30, 123.30, 122.77, 121.02, 118.36, 118.33, 111.83, 111.46, 39.71, 25.29.

(E)-3-(4-chlorophenyl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)acrylamide (3p). Yellow powder. ¹H NMR (400 MHz, DMSO-d₆) δ 10.62 (d, J = 2.3 Hz, 1H), 8.21 (t, J = 5.8 Hz, 1H), 7.58–7.51 (m, 2H), 7.48–7.42 (m, 2H), 7.39 (d, J = 15.8 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 2.3 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.67 (dd, J = 8.7, 2.4 Hz, 1H), 6.61 (d, J = 15.9 Hz, 1H), 3.71 (s, 3H), 3.43 (q, J = 6.8 Hz, 2H), 2.82 (t, J = 7.3 Hz, 2H).; ¹³C NMR (101 MHz, DMSO) δ 164.81, 153.08, 137.21, 134.04, 133.89, 131.49, 129.29, 129.07, 127.66, 123.46, 123.32, 112.12, 111.71, 111.20, 100.22, 55.40, 40.02, 25.31.

4. Conclusions

In conclusion, the highly efficient synthesis of cinnamamides from methyl cinnamates and phenylethylamines catalyzed by Lipozyme^® TL IM under continuous-flow microreactors was developed. Lipozyme^® TL IM was first used for the synthetic reaction of cinnamamides from methyl cinnamates and phenylethylamines by ammonolysis reaction. Combined with the specificity of enzyme catalysis and the efficiency of continuous-flow technology, the effects of reaction solvent, reaction temperature, reaction substrate ratio, reaction residence time, and reactant structure on the synthesis of cinnamamides were studied. The remarkable features of this study include short residence time (40 min), mild temperature (45 °C), environmental protection of catalysts, and easy control of the reaction process. Next, we will delve into more syntheses of cinnamamides, such as different amines, and explore more efficient and green synthesis methods for cinnamamide derivatives. The synthesized cinnamamide structures can be introduced into drug molecules to prepare new composite drugs, thus laying a broader scope for drug screening.